Classical Michaelis-Menten and system theory approach to modeling metabolite formation kinetics

European Journal of Drug Metabolism and Pharmacokinetics

Volumn 29, Issue 3, 2004, Pages 205-214

  Popović, Jovan ^a  

^a UNIVERSITY OF NOVI SAD   (Serbia)

Author keywords

Kinetics; Metabolism; Michaelis Menten approach; System theory

Indexed keywords

ACETYLSALICYLIC ACID; ALPRENOLOL; AMITRIPTYLINE; CARBAMAZEPINE; CHLORDIAZEPOXIDE; CODEINE; DEXTROPROPOXYPHENE; DIAZEPAM; DRUG METABOLITE; ENCAINIDE; GLUTETHIMIDE; IMIPRAMINE; ISOSORBIDE DINITRATE; LIDOCAINE; LORCAINIDE; METOPROLOL; NALOXONE; PETHIDINE; PHENACETIN; PHENOBARBITAL; PHENYLBUTAZONE; PHENYTOIN; PREDNISONE; PRIMIDONE; PROCAINAMIDE; PROPRANOLOL; QUINIDINE; SULINDAC; UNINDEXED DRUG; VERAPAMIL;

ARTICLE; CALCULATION; COMPARTMENT MODEL; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG ELIMINATION; DRUG METABOLISM; EPILEPSY; HUMAN; INTERMETHOD COMPARISON; LINEAR SYSTEM; MATHEMATICAL MODEL; MICHAELIS CONSTANT; MICHAELIS MENTEN KINETICS; NONLINEAR SYSTEM; SINGLE DRUG DOSE; SYSTEMS THEORY; THEORY;

EID: 7444239180     PISSN: 03787966     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03190599     Document Type: Article

References (50)

1. Dedík, L., Durišová, M. (1995): CXT - A programme for analysis of linear, dynamic systems in the frequency domain. Int. J. Bio-Med. Comput., 39, 231-41.
2. Dedík, L., Durišová, M. (1996): CXT-MAIN: A software package for determination of the analytical form of the pharmacokinetic system weigh ting function. Comput, Methods, Programs, Biomed., 51, 183-92.
3. Dedík, L., Durišová, M. (1999): System Approach in Technical, Environmental and Biomedical Studies. Publishing House of Slovak University of Technology, Bratislava.
4. Durišová, M., Dedík, L. (1994): Comparative study of human pentacaine pharmacokinetics in time and frequency domain. Methods. Find. Exp. Clin. Pharmacol., 16, 219-32.
5. Dedík, L., Durišová, M. (1994): Frequency response method in pharmacokinetics. J. Pharmacokin. Biopharm., 22, 293-307.
6. Durišová, M., Dedík, L., Balan, M. (1995): Building a structured model of a complex pharmacokinetic system with time delays. Bull. Math. Biol., 57, 787-808.
7. Durišová, M., Dedík, L. (1997): Modeling in frequency domain used for assessment of in vivo dissolution profile. Pharm. Res., 14, 860-4.
8. Dedík, L., Durišová, M. (2001): Modeling drug absorption from enteric coated granules. Methods. Find. Exp. Clin. Pharmacol., 23, 213-7.
9. Dedík, L., Durišová, M. (2002): System-approach methods for modeling and testing similarity of in vitro dissolutions of drug dosage formulations. Comput. Methods. Programs. Biomed., 69, 49-55.
10. Dedík, L., Durišová, M. (2002): System-approach to modeling metabolite formation from parent drug: a working example with methotrexate. Methods Find. Exp. Clin. Pharmacol., 24, 481-486.
11. Popović J. (1999): Derivation of Laplace transform for the general disposition deconvolution equation in drug metabolism kinetics. Exp. Toxic. Pathol., 51, 409-411.
12. Bray, H.G., Thorpe, W.V. and White, K. (1951): Kinetic Studies of the Metabolism of Foreign Organic Compounds I. Benzyl Alcohol and Benzaldehyde and Its Conjugation with Glycine and Glucuronic Acid in the Rabbit, Biochem. J., 48, 88-96.
13. Krüger-Thiemer, E. (1968): Pharmacokinetics and Dose - Concentration Relationship, IIIrd. Intern. Pharmacol. Meeteng, Sao Paulo 1966, Proc. 7, 63-113.
14. Krüger-Thiemer, E. (1968): Nonlinear Dose - Concentration Relationship. Farmaco (Pavia) Ed. Sci., 23, 717-756.
15. Henri, V. (1901): Compt. Rendu Hebd. Séanc. Acad. Sci. (Paris), 133, 891.
16. Briggs, G.E., Haldone, J.B.S. (1925): Biochem. J., 19, 383.
17. Botts, J., Morales, M. (1953): Faraday Soc. Trans., 49, 696, and (1958) :54, 593.
18. Botts, J., Morales, M. (1953): Faraday Soc. Trans., 49, 696, and (1958) :54, 593.
19. Walter, C. (1974): Graphical Procedure for the Detection of Deviations from the Classical Model of Enzyme Kinetics. J. Biol. Chem., 249, 699-703.
20. Michaelis, L., Menten, M.L. (1913): Die Kinetik der Invertinwirkung. Biochem. Z., 49, 333-369.
21. Gibaldi M., Boyes N.R., Feldman S. (1971): Influence of first-pass effect on availability of drugs on oral administration. J. Pharm. Sci., 60:1338-1340
22. Vaughan P.D. (1975): Estimation of biological availability after oral drug administration when the drug is eliminated by urinary excretion and metabolism. J. Pharm. Pharmac., 27:458-461
23. Rubin M.G., Tozer N.T. (1984): Theoretical considerations in the calculation of bioavailability of drugs exhibiting Michaelis-Menten elimination kinetics. J. Pharmacokin. Biopharm., 12:437-450
24. Popović J, Banić B., Popović V. (1982): Biomathematical model for individualization of dosages for drugs with non-linear pharmacokinetic behaviour. Period, biol., 84, 176-179.
25. Popović J. (1985): Kinetic model of a drug with parallel first-order and capacity-limited elimination and its application. Jugoslav. Physiol. Pharmacol. Acta, 21, Suppl. 3, 287-288.
26. Popović J. (1985): Influence of first-pass effect on availability of drugs with simultaneous biotransformation in the liver and first-order elimination through the kidneys. Jugoslav. Physiol. Pharmacol. Acta, 21, Suppl. 3, 289-290.
27. Popovic J. (1986): Dosage regimen calculations for drugs with first-order absorption, non-linear first-pass metabolism and parallel non-linear and first-order elimination. Period, biol., 88 (2), 183-184.
28. Popovic J. (1987): Relationship between the steady-state serum level and the dose of drugs with first-pass and parallel michaelis-menten and first-order elimination. Acta pharmaceutica jugoslavica. Vol. 37, No. 4, 313-317.
29. Popović J. (author) (1992): Steady-state pharmacokinetics and dosing of phenytoin and phenobarbital in patients, In: Sunchine I (ed): Recent developments in therapeutic drug monitoring. New York, Basel, Hong Kong, Marcel Dekker, Inc.Chapter 61, pages 409-414.
30. Popovic J. (1994): Toxicokinetic model of xenobiotic with parallel first order and capacity-limited elimination and its application on simulated data. Arch. Toxicol. Kinet. Xenobiot. Metab., 2(2), 417-418.
31. Richens A., Dunlop, A. (1975): Serum phenytoin levels in management of epilepsy. Lancet, 2, 247-24.
32. M. T. Ludden, W. D. Hawkins, P.J. Allen, and F. S. Hoffman. (1976): Optimum phenytoin dosage regimens. Lancet, 7, 307-308.
33. Ludden M. T., Allen P. J., Valutsky A. W., et al. (1977): Individualization of phenytoin dosage regimens. Clin. Pharmacol. Ther., 21, 287-293.
34. Mullen P. (1978): Optimal phenytoin therapy: A new technique for individualizing dosage. Clin. Pharmacol. Ther., 23, 228-232.
35. Wagner G. J. (1978): Time to reach steady-state and prediction of steady-state concentrations for drugs obeying Michaelis-Menten elimination kinetics. Pharmacokinet. Biopharm., 6, 209-225.
36. Mullen W. P., Foster W. P. (1979): Comparative evaluation of six techniques for determining the Michaelis-Menten parameters relating phenytoin dose and steady-state serum concentrations. J. Pharm. Pharmacol., 31, 100-104.
37. Ludden M. T. (1980): Individualization of phenytoin therapy. Pharm. Pharmacol., 32, 152.
38. Schumacher E. G. (1980): Using pharmacokinetics in drug therapy VI: Comparing methods for dealing with nonlinear drugs like phenytoin. Am. I. Hosp. Pharm., 37, 128-132.
39. Vozeh S., Muir T. K., Sheiner B. L., Follath F. (1981): Predicting individual phenytoin dosage. J. Pharmacokinet. Biopharm., 9, 131-146.
40. Soldin J. S., Gilbert-Hill J. (1976): Rapid micromethod for measuring anticonvulsant drugs in serum by high-performance liquid chromatography. Clin. Chem., 22, 856-859.
41. Chiba K., Ishizaki T., Miura H., Minagawa K. (1980): Michaelis-Menten pharmacokinetics of diphenylhydantoin and application in the pediatric age patient. J. Pediatr., 96, 479-494.
42. Koren G., Brand N., MacLeod M. S. (1984): Influence of bioavailability on the calculated. Michaelis-Menten parameters of phenytoin in children. Ther. Drug Monitor., 6, 11-14.
43. Vazquez Rodriguez A., (1991): Comparison of methods for the prediction of phenytoin concentrations. J. Clin. Pharm. Ther., 16(1), 55-62
44. Cai W.M., (1991): A Bayesian qraphic method for predicting individual phenytoin dosage schedule. Zhongguo Vao Li Xue Bao, 12 (2), 141-4.
45. Armijo J. A., (1991): Graphic estimation of phenytoin dose in adults and children. Ther. Drug. Monit., 13 (6), 507-10.
46. Burger D.M., (1994): Therapeutic drug monitoring of phenytoin in patients with the acquired immunodeficiccy syndrome. Ther. Drug. Monit., 16 (6), 616-20.
47. Wang X. (2003): A comparison of central (cerebrospinal and extracellular fluids) and peripheral blood kinetics of phenytoin after intravenous phenytoin andfosphenytoin. Seizure, 12 (6), 330-6.
48. Martinelli E.F. (2003): Rapid i.v. loading with phenytoin with subsequent dose adaptation using non-steady-state serum levels and a Bayesian forecasting computer program to predict maintenence doses. J. Clin. Pharm, Ther., 28 (5), 385-93
49. Purkins L. (2003): Coadministration of voriconazole and phenytoin: pharmacokinetic interaction, safety, and toleration. Br. J. Clin. Pharmacol., 56 (1), 37-44.
50. Click T.H. (2004): Preventing phenytoin intoxication: safer use of a familiar anticonvulsant. J. Farm. Pract., 53 (3), 197-202.